Search Result

Results for "

PPARγ Agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGC-1α (1) 17β-HSD (1) Adenosine Receptor (1) Akt (5) Aldose Reductase (1) Amyloid-β (2) Androgen Receptor (2) Angiotensin Receptor (4) Antibiotic (4) Apoptosis (19) Autophagy (12) Bacterial (9) Biochemical Assay Reagents (2) Bombesin Receptor (1) Calcium Channel (1) Cannabinoid Receptor (1) CaSR (1) COX (6) Cytochrome P450 (5) Drug Derivative (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (14) Environmental Pollutants (1) Epoxide Hydrolase (1) ERK (7) Estrogen Receptor/ERR (3) Fatty Acid Synthase (FASN) (1) Ferroptosis (18) Free Fatty Acid Receptor (4) Fungal (2) Glucocorticoid Receptor (1) Glutathione Peroxidase (1) Glycosidase (2) HIF/HIF Prolyl-Hydroxylase (3) HIV (2) Integrin (2) Interleukin Related (5) Isotope-Labeled Compounds (17) JNK (3) Keap1-Nrf2 (3) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) LXR (4) Mitochondrial Metabolism (1) Monoamine Oxidase (1) mTOR (2) NEKs (1) NF-κB (18) NO Synthase (2) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (2) PAK (8) PARP (1) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (3) PKC (2) PPAR (224) Prostaglandin Receptor (4) PTEN (2) RAR/RXR (6) Reactive Oxygen Species (ROS) (1) Reference Standards (34) ROR (1) Sirtuin (2) SOD (1) Src (2) STAT (2) TGF-beta/Smad (2) TNF Receptor (2) Toll-like Receptor (TLR) (2) TRP Channel (8) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (75) Cardiovascular Disease (31) Endocrinology (7) Infection (7) Inflammation/Immunology (73) Metabolic Disease (159) Neurological Disease (32)
Click Chemistry:	Alkynes (1)

240

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13956

Pioglitazone 45+ Cited Publications U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-50935

Troglitazone 30+ Cited Publications CS-045	PPAR Autophagy Apoptosis Ferroptosis	Metabolic Disease Cancer
Troglitazone is an orally active *PPARγ* agonist, with EC₅₀s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.

HY-16995

Pirinixic acid 30+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-14601

Pioglitazone hydrochloride 45+ Cited Publications U 72107A; AD 4833	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone hydrochloride is a potent and selective *PPARγ* agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-15655

GW1929 10+ Cited Publications	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ*, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ* and PPARδ, and 90 μM, 55 μM, 110 μM for *murine PPARα, PPARγ* and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-N0246

Saikosaponin A 5 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-B0287

Clofibrate 4 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ*, respectively.

HY-N2025

Oroxin A 4 Publications Verification	PPAR Glycosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial *PPARγ* agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-16086

Balaglitazone 1 Publications Verification DRF 2593; NN 2344	PPAR	Metabolic Disease
Balaglitazone is a selective partial *PPARγ* agonist with an EC₅₀ of 1.351 μM for human *PPARγ*.

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-148351

BAY-0069	PPAR	Cancer
BAY-0069 is a potent and selective *PPARγ* inverse agonist with an IC₅₀ value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer .

HY-U00450

4-O-Methyl honokiol	PPAR NF-κB	Inflammation/Immunology Cancer
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a *PPARγ* agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

HY-14792B

Inolitazone dihydrochloride 5 Publications Verification Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride	PPAR	Cancer
Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity *PPARγ* agonist that is dependent upon PPARγ for its biological activity with IC₅₀ of 0.8 nM for growth inhibition.

HY-148352

BAY-4931 1 Publications Verification	PPAR	Cancer
BAY-4931 is a potent, covalent and selective *PPARγ* inverse-agonist with an IC₅₀ of 0.17 nM .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and *PPARγ* agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-14601R

Pioglitazone hydrochloride (Standard) U 72107A (Standard); AD 4833 (Standard)	Reference Standards PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective *PPARγ* agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active *PPARγ* agonist, with EC₅₀s of 35.6 nM and 1053 nM for PPARα and *PPARγ*, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-N9333

Wistin	PPAR	Metabolic Disease Cancer
Wistin, isolated from Caragana sinica roots, is a PPARα and *PPARγ* agonist .

HY-122235

MRL-24	PPAR	Cardiovascular Disease
MRL-24 is a *PPARγ* agonist. MRL-24 can be used in metabolic disease related research .

HY-146480

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of *PPARγ. PPARγ* agonist 5 has the potential for the research of cancer diseases .

HY-116468

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of *PPARγ* (EC₅₀: 0.1 μM) .

HY-159944

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

HY-150308

SR10221	PPAR	Cancer
SR10221, a noncovalent inverse agonist of *PPARγ, represses downstream PPARγ* target genes leading to growth inhibition in bladder cancer cell lines .

HY-13956S1

Pioglitazone-d4 (alkyl)	Isotope-Labeled Compounds PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ (alkyl) (U 72107-d₄ (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-17386S

Rosiglitazone-d3	Isotope-Labeled Compounds PPAR TRP Channel Autophagy Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC₅₀=~30 μM) and an inhibitor of TRPM3 .

HY-14831

Arhalofenate 1 Publications Verification MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes.

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-W341997

9-Octadecynoic acid	PPAR	Metabolic Disease
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-146482

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of *PPARγ. PPARγ* agonist 6 has the potential for the research of cancer diseases .

HY-162320

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective *PPARγ* agonist with EC₅₀s of 3.98 and 15.42 μM against *PPARγ* and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

HY-178447

PPARγ agonist 20	PPAR Glutathione Peroxidase SOD TNF Receptor Interleukin Related NF-κB	Infection Metabolic Disease Endocrinology
PPARγ agonist 20 is a potent, orally active *PPAR-γ* agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .

HY-14792

Inolitazone Efatutazone; CS-7017; RS5444	PPAR	Cancer
Inolitazone a novel high-affinity *PPARγ* agonist that is dependent upon PPARγ for its biological activity with IC₅₀ of 0.8 nM for growth inhibition.

HY-138007

SR-1903	ROR PPAR LXR	Metabolic Disease Inflammation/Immunology
SR-1903 is an inverse agonist of RORγ and *PPARγ* (IC₅₀ of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .

HY-101292

FK614	PPAR	Metabolic Disease
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective *PPARγ* modulator (SPPARM). FK614 functions as a *PPARγ* agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of *PPARγ* at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

HY-B0287R

Clofibrate (Standard) 4 Publications Verification	Reference Standards PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ*, respectively.

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of *PPARγ. PPARγ* agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	PPAR	Cancer
Methyl oleanonate is a natural triterpene *PPARγ* agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-146438

PPARγ agonist 3	PPAR	Cancer
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .

HY-146439

PPARγ agonist 4	PPAR	Cancer
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of *PPARγ. PPARγ* agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .

HY-147511

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

HY-153982

PPARγ agonist 8	PPAR	Metabolic Disease
PPARγ agonist 8 is an agonist of *PPARγ. PPARγ* agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC₅₀ of 0.2 μM .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of *PPARγ. PPARγ* agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-168719

PPARγ agonist 16	PPAR	Inflammation/Immunology
PPARγ agonist 16 (Compound 4G) is the agonist for *PPARγ, that competitively binds to LBD domain of PPARγ* with IC₅₀ of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .

HY-146742

PPARγ agonist 2	PPAR	Metabolic Disease
PPARγ agonist 2 is a potent *PPARγ* partial agonist and can be used for metabolic disease research .

HY-169404

PPARγ agonist 15	PPAR	Metabolic Disease
PPARγ agonist 15 (Compound 7c) is an agonist for *PPARγ. PPARγ* agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC₅₀ of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .

HY-176214

PPARγ agonist 19	PPAR COX	Metabolic Disease
PPARγ agonist 19 (Compound 5e) is a *PPARγ* agonist. PPARγ agonist 19 has an IC₅₀ of 11.27 μM against COX-1 and an IC₅₀ of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .

HY-163294

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a *PPARγ* agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

Cat. No.	Product Name	Target	Research Area

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15027

5-Aminosalicylic Acid Maximum Cited Publications 33 Publications Verification Mesalamine; 5-ASA; Mesalazine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-N0163

Magnolol 5+ Cited Publications	Cardiovascular Disease Neurological Disease Classification of Application Fields Lignans Plants Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Polyphenols Phenylpropanoids Inflammation/Immunology Disease Research Fields Source Classification	RAR/RXR PPAR Autophagy Bacterial
Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and *PPARγ, with EC₅₀* values of 10.4 µM and 17.7 µM, respectively.

HY-N0246

Saikosaponin A 5 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Umbelliferae Plants Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification Cancer	LXR Bacterial
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N0234

Bavachinin 5+ Cited Publications 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 2 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective *PPARγ* (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-N6641

Monascin 2 Publications Verification	Natural Products Microorganisms other families Classification of Application Fields Pigments Plants Inflammation/Immunology Disease Research Fields Source Classification Food Research	Keap1-Nrf2 PPAR
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and *PPARγ* agonist .

HY-N2025

Oroxin A 4 Publications Verification	Flavonoids Classification of Application Fields Flavones Metabolic Disease Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Disease Research Fields Source Classification	PPAR Glycosidase
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial *PPARγ* agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-N6869

Dehydroabietic acid 1 Publications Verification	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N6642

Ankaflavin	Natural Products Microorganisms Classification of Application Fields Plants Inflammation/Immunology Disease Research Fields Source Classification	PPAR Apoptosis
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active *PPARγ* agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .

HY-N15574

Saringosterol	Structural Classification Marine algae Marine natural products Steroids Source Classification	LXR Bacterial PPAR
Saringosterol is an orally active steroid found in Sargassum muticum. Saringosterol is a LXR agonist. Saringosterol can lower cholesterol levels and inhibit the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα). Saringosterol has anti-obesity, anti-atherosclerosis, anti-Mycobacterium tuberculosis and anti-depressant activities .

HY-N10361

Drupanin	Monophenols Animals Classification of Application Fields Phenols Disease Research Fields Source Classification Cancer	RAR/RXR PPAR Aldose Reductase
Drupanin is an orally active and selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC₅₀ value of 4.8 μM, which is found in green propolis. Drupanin also activates *PPARγ* moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .

HY-N2110

Phellopterin	Structural Classification Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Inflammation/Immunology Disease Research Fields Source Classification	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing *PPARγ*. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-U00450

4-O-Methyl honokiol	Classification of Application Fields Lignans Plants Monophenols other families Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Phenylpropanoids Inflammation/Immunology Disease Research Fields Source Classification Cancer	PPAR NF-κB
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a *PPARγ* agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

HY-N7043

Isosilybin A 2 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Source Classification Cancer	Apoptosis PPAR NF-κB p38 MAPK ERK Androgen Receptor
Isosilybin A is a *PPARγ* agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity ^[1][2][3].

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	PPAR
Wistin, isolated from Caragana sinica roots, is a PPARα and *PPARγ* agonist .

HY-113631

Amorfrutin B	Monophenols Leguminosae Phenols Amorpha fruticosaL. Plants Source Classification	PPAR
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-15027R

5-Aminosalicylic Acid (Standard) Mesalamine (Standard); 5-ASA (Standard); Mesalazine (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Phenols Endogenous metabolite Source Classification	Reference Standards PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-119790

Palmitoyllactic acid	Structural Classification Animals Ketones, Aldehydes, Acids Source Classification	PPAR
Palmitoyllactic acid is a long-chain fatty acid with lipogenic activity. Palmitoyllactic acid can induce a brown fat-like phenotype in 3T3-L1 cells. Palmitoyllactic acid enhances the expression of a variety of brown/beige cell-specific genes, such as Prdm16 and Pgc1a. Palmitoyllactic acid acts similarly to PPARγ agonists, significantly enhancing adipogenesis in the presence of dexamethasone. Palmitoyllactic acid can be used in obesity research .

HY-W341997

9-Octadecynoic acid	Structural Classification Leguminosae Paramacrolobium coeruleum (Taub.) J.Léonard Ketones, Aldehydes, Acids Plants Source Classification	PPAR
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	Triterpenes Pistacia lentiscus var. Chia other families Classification of Application Fields Terpenoids Plants Disease Research Fields Cancer Source Classification Anacardiaceae	PPAR
Methyl oleanonate is a natural triterpene *PPARγ* agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-13956R

Pioglitazone (Standard) U 72107 (Standard)	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	Reference Standards PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N0246R

Saikosaponin A (Standard)	Triterpenes Structural Classification Terpenoids Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	Reference Standards LXR Bacterial
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N7687

Caulophyllogenin	Triterpenes Classification of Application Fields Leguminosae Terpenoids Acacia catechu (Linn. f.) Willd. Plants Disease Research Fields Inflammation/Immunology Source Classification	PPAR
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial *PPARγ* agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-N0163R

Magnolol (Standard)	Structural Classification Magnolia officinalis. Rehd. et Wils. Magnoliaceae Lignans Phenols Polyphenols Phenylpropanoids Plants Source Classification	Reference Standards RAR/RXR PPAR Autophagy Bacterial
Magnolol (Standard) is the analytical standard of Magnolol. This product is intended for research and analytical applications. Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.

HY-N2110R

Phellopterin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Source Classification	Reference Standards Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing *PPARγ*. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.

HY-N2025R

Oroxin A (Standard)	Structural Classification Flavonoids Flavones Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Source Classification	Reference Standards PPAR Glycosidase
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-U00450R

4-O-Methyl honokiol (Standard)	Structural Classification Monophenols other families Magnolia officinalis. Rehd. et Wils. Magnoliaceae Lignans Phenols Phenylpropanoids Plants Source Classification	Reference Standards PPAR NF-κB
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a PPARγ agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Diterpenoids Plants Source Classification	Antibiotic Reference Standards PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N6641R

Monascin (Standard)	Structural Classification Natural Products Microorganisms other families Plants Source Classification	Reference Standards Keap1-Nrf2 PPAR
Monascin (Standard) is the analytical standard of Monascin. This product is intended for research and analytical applications. Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .

HY-N7043R

Isosilybin A (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Reference Standards Apoptosis PPAR NF-κB p38 MAPK ERK Androgen Receptor
Isosilybin A (Standard) is the analytical standard of Isosilybin A (HY-N7043). Isosilybin A is a *PPARγ* agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity ^[1][2][3].

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Source Classification	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N18020

Saurufuran A	Structural Classification Saururaceae Saururus chinensis (Lour.) Baill. Ketones, Aldehydes, Acids Plants Source Classification	Others
Saurufuran A is a *PPARγ* agonist with an EC₅₀ of 16.7 μM. Saurufuran A is applicable to research related to type 2 diabetes, inflammatory diseases and certain cancers .

HY-127003

Neoambrosin	Structural Classification Ambrosia maritima L. Terpenoids Diterpenoids Plants Compositae Source Classification	PPAR TRP Channel
Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of *PPARγ* and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects .

Cat. No.	Product Name	Chemical Structure

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-17386S1

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective *PPARγ* agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-13956S1

Pioglitazone-d4 (alkyl)
Pioglitazone-d₄ (alkyl) (U 72107-d₄ (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .

HY-17386S

Rosiglitazone-d3
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC₅₀=~30 μM) and an inhibitor of TRPM3 .

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-50935S

Troglitazone-d4
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-14728S

Deutaleglitazar
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and *PPARγ*) .

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-15027S4

5-Aminosalicylic acid-d7
5-Aminosalicylic acid-d₇ (5-ASA-d₇; Mesalamie-d₇; Mesalazie-d₇) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-181896S

PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active *PPARγ* agonist with an EC₅₀ of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .

HY-13956S

Pioglitazone-d4
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-W738533

Pioglitazone-d4 hydrochloride
Pioglitazone-d₄ hydrochloride (U 72107A-d₄; AD 4833-d₄) is the deuterium labeled Pioglitazone hydrochloride (HY-14601). Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ* and PPARδ, and 90 μM, 55 μM, 110 μM for *murine PPARα, PPARγ* and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-107333S

Cinoxate-d3
Cinoxate-d₃ is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with K_i value of 18.0 μM. Cinoxate can be used to study obesity .

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-15027S3

5-Aminosalicylic acid-d3 disodium
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-W654296

Octocrylene-13C3

Octocrylene- ¹³C₃ is the ¹³C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .

HY-116028S1

15-deoxy-Δ12,14-Prostaglandin D2-d4

15-Deoxy-Δ12,14-Prostaglandin D2-d₄ (15-Deoxy-Δ12,14-PGD2-d₄) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.

Cat. No.	Product Name		Classification

HY-173115

15-LOX-IN-2		Alkynes
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of *PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β* and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks